Mycophenolic Acid
NDC Package 24979-161-44
Package Information
Mycophenolic Acid is delayed-release tablets are indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant.Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant.Mycophenolic acid delayed-release tablets are to be used in combination with cyclosporine and corticosteroids. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 24979-161 and is authorized under FDA application ANDA214289.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 24979 - Upsher-smith Laboratories, Llc
- 24979-161 - Mycophenolic Acid
- 24979-161-44 - 120 TABLET, DELAYED RELEASE in 1 BOTTLE
- 24979-161 - Mycophenolic Acid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 24979-161-44 identifies a specific commercial package of 120 tablet, delayed release in 1 bottle of Mycophenolic Acid, labeled by Upsher-smith Laboratories, Llc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Upsher-smith Laboratories, Llc on November 08, 2021. The current certification is valid through September 30, 2026.
How is this Upsher-smith Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 24979016144. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
